- Conditions
- Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
- Interventions
- ocriplasmin 0.0625mg, ocriplasmin 0.125mg, Sham injection
- Drug
- Lead sponsor
- ThromboGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Campbell, California • Irvine, California + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 62
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Intravitreal Aflibercept Injection (IAI)
- Drug
- Lead sponsor
- Ophthalmic Consultants of Long Island
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Lynbrook, New York
- Conditions
- Non-Proliferative Diabetic Retinopathy
- Interventions
- Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24, Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24, Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24
- Drug · Other
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 930 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Hagerstown, Maryland
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
- Drug
- Lead sponsor
- Retina Consultants of Orange County
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Fullerton, California
- Conditions
- Moderate Non-proliferative Diabetic Retinopathy
- Interventions
- Alpha Lipoic Acid
- Dietary Supplement
- Lead sponsor
- Ferris State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Big Rapids, Michigan • Grand Rapids, Michigan
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Prompt Panretinal Photocoagulation, 0.5-mg Ranibizumab, Deferred panretinal photocoagulation
- Other · Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Loma Linda, California • Palm Springs, California + 42 more
- Conditions
- Diabetic Retinopathy
- Interventions
- Octreotide Acetate in Microspheres, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema, Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
- Interventions
- INV-102
- Drug
- Lead sponsor
- Invirsa, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
- Interventions
- APX3330, Placebo
- Drug
- Lead sponsor
- Ocuphire Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more
- Conditions
- Diabetic Retinopathy
- Interventions
- Fenofibrate, Placebo
- Drug · Other
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 563 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 66
- States / cities
- Glendale, California • Huntington Beach, California • Loma Linda, California + 55 more
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Lucentis (ranibizumab)
- Drug
- Lead sponsor
- Retina Associates, Kansas City
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Shawnee Mission, Kansas
- Conditions
- Nonproliferative Diabetic Retinopathy
- Interventions
- AKB-9778, Placebo
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 53
- States / cities
- Phoenix, Arizona • Arcadia, California • Bakersfield, California + 47 more
- Conditions
- Retinal Neovascularization
- Interventions
- Squalamine Lactate ophthalmic solution 0.2%
- Drug
- Lead sponsor
- Elman Retina Group
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetic Retinopathy
- Interventions
- Vitreosolve
- Drug
- Lead sponsor
- Vitreoretinal Technologies, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Santa Ana, California + 7 more
- Conditions
- Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
- Interventions
- Faricimab Injection, sham treatment
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
- Interventions
- multi-component nutritional supplement capsules, multi-component dietary supplement
- Dietary Supplement
- Lead sponsor
- ZeaVision, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Diabetic Retinopathy
- Interventions
- OTT166, Vehicle control
- Drug
- Lead sponsor
- OcuTerra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 67
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 59 more
- Conditions
- Diabetic Retinopathy
- Interventions
- doxycycline monohydrate, placebo
- Drug
- Lead sponsor
- Thomas Gardner
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Aflibercept, Endolaserless Vitrectomy
- Drug · Procedure
- Lead sponsor
- Southeast Retina Center, Georgia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Retinopathy, Diabetic
- Interventions
- Aflibercept Injection, Sham injection
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
- Interventions
- 2-mg Intravitreous Aflibercept Injection, Prompt Vitrectomy Plus Panretinal Photocoagulation
- Drug · Procedure
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 60
- States / cities
- Campbell, California • Glendale, California • Huntington Beach, California + 50 more
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Macugen, Sham
- Drug
- Lead sponsor
- Greater Houston Retina Research
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Proliferative Diabetic Retinopathy - High Risk
- Interventions
- laser indirect ophthalmoscopy pan retinal photocoagulation
- Procedure
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetic Retinopathy
- Interventions
- Octreotide Acetate in Microspheres 20 mg, Octreotide Acetate in Microspheres, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey